Where to Access the Poster Presentations?
Poster presentations are only made in person during dedicated sessions, they are not broadcasted but the files can be viewed on the virtual portal if you are registered for the meeting once the event ends.
Each presentation is 7 min long (5 min presentation + 2 min Q&A), followed by 2 min free between each presentations.
Poster booths are located in the Foyer (booths A, C, D, E) and Exhibition area (booth B) of the Grand Hyatt Melbourne; check your schedule and booths below:
Oral Posters
Please note all timings are based on Melbourne time zone.
➜ Australian Eastern Standard Time (AEDT) – UTC+11
20251108043720
Posters on Displays
These Posters are available on the laptops in the Poster Booths during the whole meeting, and/or through the virtual portal.
| Abstract | Author/Presenter |
| #1007 | Francesco LEO Minimal disease activity as a new therapeutic target in atopic dermatitis: a 5-year real-life experience with dupilumab |
| #1008 | Rui CHEN The association of atopic multimorbidity with childhood cat exposure, farm living, and rural residence: results of the Lifelines cohort study |
| #1013 | Zhixuan LI Global, regional and national burdens of atopic dermatitis in adolescents and young adults aged 10-24 years from 1990 to 2021: a trend analysis |
| #1015 | Yuyang LIU Healing Beyond the Surface: A systematic review of Integrative Approaches to Sleep Management in Atopic Dermatitis |
| #1017 | Mutong ZHAO Multi-omics profiling of the 42-day infant gut predicts atopic dermatitis |
| #1019 | Bernd ARENTS Optimizing topical therapy in The Netherlands: the Dutch National Atopic Dermatitis Project |
| #1026 | Madeleine NEILDEZ Risk of Major Adverse Cardiovascular Events in Adults Treated with JAK Inhibitors for Atopic Dermatitis: A nationwide population-based study using the French claims database |
| #1031 | Anna Sophie Nicolo Belling KRONTOFT Towards collaborative consultations in Atopic Dermatitis: A controlled trial on the Impact of Conversation Cards and Contact Nurses |
| #1051 | Park CHUN WOOK Optimal dose finding of TRPM8 agonist Cryosim-1 for antipruritic therapy: a randomized controlled trial |
| #1052 | Qingyang ZHAO Research Advances in Itch Mechanisms of Pediatric Atopic Dermatitis |
| #1057 | Sofia MARUSCHAK-LOVE Improving Pediatric Dermatological Care: An Educational Video that Improves Patient Knowledge and Confidence Regarding Eczema |
| #1058 | Risa TAMAGAWA-MINEOKA A Case of Morbihan Disease Complicating Refractory Facial Lesions in Atopic Dermatitis |
| #1059 | Mamoudou DIAKITÉ Associated factors to the severity of atopic dermatitis among children of 6 to 10 years in urban and rural area |
| #1066 | Marion GUNDELWEIN Real-world use of systemic treatments for severe atopic dermatitis in France between 2018 and 2023 , using the French claims database |
| #1077 | Hyun-Chang KO Analysis of correlation between ECP, IgE, allergic hypersensitivity and eczema severity in atopic dermatitis and non-atopic eczema |
| #1078 | Rodney SINCLAIR Real-World Effectiveness of Upadacitinib in Atopic Dermatitis Based on Prior Exposure to Biologic Therapy: 6-Month Interim Analysis of the Multicountry AD-VISE Study |
| #1082 | Seong Jun SEO Efficacy and safety of autologous adipose-derived stem cells in subjects with moderate to severe atopic dermatitis: a multicenter, randomized, single-blind, placebo-controlled, phase 2 trial |
| #1084 | Martina KOJANOVA Lebrikizumab for the treatment of severe atopic dermatitis: Real- world data from the Czech Republic BIOREP Registry |
| #1094 | Amina Nomtondo OUEDRAOGO Atopy and Allergic Contact Dermatitis in Ouagadougou |
| #1095 | Paulina BARASIŃSKA Methotrexate use in pediatric atopic dermatitis: final results from the STEADY study (Systemic Treatment Efficacy in Atopic Dermatitis in Young Children and Adolescents) |
| #1096 | Lin MA Real-World Dupilumab Use in Chinese Infants, Children and Adolescents with Atopic Dermatitis: Patient- and Caregiver-Reported Outcomes in the ADOPED-STAD Study |
| #1097 | Huilan ZHU The GSDMD-mediated keratinocytes pyroptosis regulates T cell homeostasis through HMGB1/NF-κB pathway to promote atopic dermatitis |
| #1098 | Lew BARK-LYNN Modifying Dupilumab Dosing Frequency in Patients with Psoriasiform Dermatitis: A Case-Based Approach |
| #1111 | Hilina Tekola MESHESHA Assessment of Atopy historybin infantile atopic dermatitis patients attending dermatology clinic at ALERT hospital |
| #1114 | Marta Dominika MATYCH Real-World Assessment of Upadacitinib for Atopic Dermatitis: Effectiveness and Safety from a Single-Center Retrospective Analysis |
| #1120 | Ki Chan KIM Therapeutic Potential of Asarinin in an Atopic Dermatitis Mouse Model: Suppression of Inflammatory Responses and Skin Lesions |
| #1121 | Peter SCHMID-GRENDELMEIER Dupilumab Treatment Across Dose Regimens Maintains Improvement in Atopic Dermatitis Signs and Symptoms and Quality of Life for 100 Weeks |
| #1127 | Alexander JAFARI Measuring atopic dermatitis severity from the patient perspective in a pediatric dermatology clinic |
| #1140 | Andrianarison MALALANIAINA Atopic Dermatitis in Older Patients: What About Methotrexate? |
| #1149 | Mike BASTIAN Anchored Matching-Adjusted Indirect Comparison of Treatment Efficacy Between Dupilumab and Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis |
| #1151 | Chan-Ho NA Evolving Aesthetic Expectations in Patients with Moderate-to-Severe Atopic Dermatitis amidst Emerging Targeted Therapies |
| #1155 | Ludivine CANCHY In Vitro Triage of Anti Pruritic Compounds |
20251108043720